Conferences - Results from #8500

Viewing 8501-8520 of 11775 articles

SUO 2017: Predictors Of Early Disease Specific Mortality Among Patients With Prostate Adenocarcinoma Bone Metastasis At Diagnosis

SUO 2017: Utilization of BCG for Non-Muscle Invasive Bladder Cancer in an Era of BCG Supply Shortages

SUO 2017: External Validation of EORTC Bladder Cancer Risk Calculator in a Contemporary US Population

SUO 2017: Inaccuracy of Clinical Staging After Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

SUO 2017: Neoadjuvant Chemotherapy with Dose Dense MVAC, Associated with Higher Down Staging and Pathologic T0 Rates after Radical Cystectomy

SUO 2017: Survival Outcomes For African-American Versus Matched Caucasian Patients With mCRPC Treated With Sipuleucel-T

SUO 2017: Long Term Outcomes For Patients With Von Hippel Lindau And Pheochromocytoma: Defining The Best Candidates For Active Surveillance

SUO 2017: Toward Better Clinical Staging - Molecular Imaging in Muscle Invasive and Metastatic Bladder Cancer

SUO 2017: Prostate Cancer Incidence, Treatment Trends, and Survival Among American Indians and Alaskan Natives in The U.S

SUO 2017: Robot-assisted Versus Laparoscopic Nephroureterectomy For Upper Tract Urothelial Carcinoma: Short-term Outcomes From The National Cancer Database

SUO 2017: Neoadjuvant Therapies in Kidney Cancer: Critique, Current Trials and Future Directions

SUO 2017: Bladder Cancer: Upcoming Immunotherapy Ongoing Trials and Early Data

SUO 2017: Management of Immune-Related Toxicity with Checkpoint Inhibitors in Bladder Cancer Patients

SUO 2017: Metastasis-Free Survival Endpoint

SUO 2017: Bladder Cancer: Currently Approved Immunotherapy

SUO 2017: Biology and Management of MIBC and Oligometastatic Bladder Cancer – What is the Role of Surgery?

SUO 2017: Renal Cell Carcinoma: Emerging Data for Locally Advanced and Metastatic Disease

SUO 2017: Rationale, Pitfalls and Actionable Results of Genomic Testing in Developing Neoadjuvant and Adjuvant Strategies

SUO 2017: Update on The Cancer Genome Atlas (TCGA)

SUO 2017: Biology and Management of MIBC and Oligometastatic Bladder Cancer – Clonal Evolution in Metastatic Urothelial Cancer

421
422
423
424
425
426
427
428
429
430